학술논문
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
Document Type
Article
Author
Source
American Journal of Hematology; May2017, Vol. 92 Issue 5, p460-466, 7p
Subject
Language
ISSN
03618609